173 related articles for article (PubMed ID: 23768699)
1. Effects of agomelatine in a murine model of obsessive-compulsive disorder: interaction with meta-chlorophenylpiperazine, bicuculline, and diazepam.
Bhutada P; Dixit P; Thakur K; Deshmukh P; Kaulaskar S
Kaohsiung J Med Sci; 2013 Jul; 29(7):362-7. PubMed ID: 23768699
[TBL] [Abstract][Full Text] [Related]
2. Agomelatine(S 20098) antagonizes the penile erections induced by the stimulation of 5-HT2C receptors in Wistar rats.
Chagraoui A; Protais P; Filloux T; Mocaër E
Psychopharmacology (Berl); 2003 Oct; 170(1):17-22. PubMed ID: 12904965
[TBL] [Abstract][Full Text] [Related]
3. Agomelatine, a melatonin agonist with antidepressant properties.
Dubovsky SL; Warren C
Expert Opin Investig Drugs; 2009 Oct; 18(10):1533-40. PubMed ID: 19758108
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system.
Fuchs E; Simon M; Schmelting B
Int Clin Psychopharmacol; 2006 Feb; 21 Suppl 1():S17-20. PubMed ID: 16436935
[TBL] [Abstract][Full Text] [Related]
5. Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: a comparison to melatonin and to the 5-HT(2c) antagonist, S32006.
Norman TR; Cranston I; Irons JA; Gabriel C; Dekeyne A; Millan MJ; Mocaër E
Eur J Pharmacol; 2012 Jan; 674(1):27-32. PubMed ID: 22040921
[TBL] [Abstract][Full Text] [Related]
6. Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties.
Guardiola-Lemaitre B; De Bodinat C; Delagrange P; Millan MJ; Munoz C; Mocaër E
Br J Pharmacol; 2014 Aug; 171(15):3604-19. PubMed ID: 24724693
[TBL] [Abstract][Full Text] [Related]
7. The mechanism, efficacy, and tolerability profile of agomelatine.
MacIsaac SE; Carvalho AF; Cha DS; Mansur RB; McIntyre RS
Expert Opin Pharmacother; 2014 Feb; 15(2):259-74. PubMed ID: 24328686
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and pharmacological evaluation of a series of the agomelatine analogues as melatonin MT1 /MT2 agonist and 5-HT2C antagonist.
Ettaoussi M; Sabaouni A; Pérès B; Landagaray E; Nosjean O; Boutin JA; Caignard DH; Delagrange P; Berthelot P; Yous S
ChemMedChem; 2013 Nov; 8(11):1830-45. PubMed ID: 24031039
[TBL] [Abstract][Full Text] [Related]
9. Synergistic mechanisms involved in the antidepressant effects of agomelatine.
Tardito D; Molteni R; Popoli M; Racagni G
Eur Neuropsychopharmacol; 2012; 22 Suppl 3():S482-6. PubMed ID: 22867907
[TBL] [Abstract][Full Text] [Related]
10. Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression.
Bourin M; Prica C
Curr Pharm Des; 2009; 15(14):1675-82. PubMed ID: 19442180
[TBL] [Abstract][Full Text] [Related]
11. Agomelatine but not melatonin improves fatigue perception: a longitudinal proof-of-concept study.
Pardini M; Cordano C; Benassi F; Mattei C; Sassos D; Guida S; Serrati C; Primavera A; Amore M; Cocito L; Emberti Gialloreti L
Eur Neuropsychopharmacol; 2014 Jun; 24(6):939-44. PubMed ID: 24636462
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of new naphtho- and quinolinocyclopentane derivatives as potent melatoninergic (MT
Duroux R; Rami M; Landagaray E; Ettaoussi M; Caignard DH; Delagrange P; Melnyk P; Yous S
Eur J Med Chem; 2017 Dec; 141():552-566. PubMed ID: 29102176
[TBL] [Abstract][Full Text] [Related]
13. Major depressive disorder, anhedonia and agomelatine: an open-label study.
Di Giannantonio M; Di Iorio G; Guglielmo R; De Berardis D; Conti CM; Acciavatti T; Cornelio M; Martinotti G
J Biol Regul Homeost Agents; 2011; 25(1):109-14. PubMed ID: 21382280
[TBL] [Abstract][Full Text] [Related]
14. [Agomelatine: the first "melatoninergic" antidepressant].
Bánki MC
Neuropsychopharmacol Hung; 2006 Oct; 8(3):105-12. PubMed ID: 17211046
[TBL] [Abstract][Full Text] [Related]
15. Agomelatine: innovative pharmacological approach in depression.
Popoli M
CNS Drugs; 2009; 23 Suppl 2():27-34. PubMed ID: 19708723
[TBL] [Abstract][Full Text] [Related]
16. Role of 5-hydroxytryptamine2C receptors in marble-burying behavior in mice.
Egashira N; Okuno R; Shirakawa A; Nagao M; Mishima K; Iwasaki K; Oishi R; Fujiwara M
Biol Pharm Bull; 2012; 35(3):376-9. PubMed ID: 22382324
[TBL] [Abstract][Full Text] [Related]
17. The melatonergic agonist and clinically active antidepressant, agomelatine, is a neutral antagonist at 5-HT(2C) receptors.
Millan MJ; Marin P; Kamal M; Jockers R; Chanrion B; Labasque M; Bockaert J; Mannoury la Cour C
Int J Neuropsychopharmacol; 2011 Jul; 14(6):768-83. PubMed ID: 20946699
[TBL] [Abstract][Full Text] [Related]
18. Activation of Melatonin Receptors Reduces Relapse-Like Alcohol Consumption.
Vengeliene V; Noori HR; Spanagel R
Neuropsychopharmacology; 2015 Dec; 40(13):2897-906. PubMed ID: 25994077
[TBL] [Abstract][Full Text] [Related]
19. Does melatonin treatment change emotional processing? Implications for understanding the antidepressant mechanism of agomelatine.
Pringle A; Bogdanovskaya M; Waskett P; Zacharia S; Cowen PJ; Harmer CJ
J Psychopharmacol; 2015 Oct; 29(10):1129-32. PubMed ID: 26174133
[TBL] [Abstract][Full Text] [Related]
20. The antipsychotic trifluoperazine reduces marble-burying behavior in mice via D
Egashira N; Kubota N; Goto Y; Watanabe T; Kubota K; Katsurabayashi S; Iwasaki K
Pharmacol Biochem Behav; 2018 Feb; 165():9-13. PubMed ID: 29273456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
